Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ipsen S.A. ADR (OP: IPSEY ) 28.50 +0.03 (+0.10%) Streaming Delayed Price Updated: 3:25 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 687 Open 28.53 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 28.47 Today's Range 28.50 - 29.04 52wk Range 26.97 - 34.34 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal July 13, 2024 In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. Via Talk Markets Topics Initial Public Offering Exposures Securities Market FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo June 11, 2024 The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... Via Benzinga Exposures Product Safety Performance YTD -4.81% -4.81% 1 Month -4.65% -4.65% 3 Month -14.16% -14.16% 6 Month -1.30% -1.30% 1 Year -9.52% -9.52% More News Read More Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing November 10, 2023 From Virtual Investor Conferences Via GlobeNewswire 3 Promising Biotech Stocks Flying Under the Radar November 08, 2023 Via InvestorPlace International companies to host live webcasts at Deutsche Bank’s Depositary Receipts November 01, 2023 From Virtual Investor Conferences Via GlobeNewswire Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients August 21, 2023 Via Benzinga Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class June 30, 2023 Via Benzinga Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients June 30, 2023 Via Benzinga What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur May 22, 2023 Via Benzinga International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 May 09, 2023 From Virtual Investor Conferences Via GlobeNewswire Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing May 18, 2023 From Virtual Investor Conferences Via GlobeNewswire Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. January 27, 2023 From Ipsen Via Business Wire Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI January 20, 2023 From Ipsen Via Business Wire International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 May 15, 2023 From Virtual Investor Conferences Via GlobeNewswire Why These Two Biotech Stocks Blasted Higher This Week January 13, 2023 Via The Motley Fool 2 Tiny Nasdaq Stocks Making Major Merger Moves Monday January 09, 2023 Via The Motley Fool France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline January 09, 2023 Via Benzinga Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases January 09, 2023 From Ipsen Via Business Wire Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva December 23, 2022 From Ipsen Via Business Wire Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting December 09, 2022 Via Benzinga Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy December 08, 2022 From Ipsen Via Business Wire Why Merrimack Shares Are Surging Over 200% Today? November 09, 2022 Via Benzinga Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma November 09, 2022 From Ipsen Via Business Wire Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know November 01, 2022 Via Benzinga Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance October 27, 2022 From Ipsen Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.